Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic LMWH for Sickle Cell Pain Crisis
NCT01419977Phase 2Completed
- Sponsor
- Duke University
- Start
- May 2011
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Dalteparin with Placebo (2 arms). Primary endpoints: Change in D-dimer at Day 3, Change in Clinical Pain Scores at Day 1 and 1 more. Started May 2011; status: completed.
02
Drugs
dalteparin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01419977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01419977.